3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Nasopharyngeal Carcinoma
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Stomach Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Prostatic Neoplasms
2
Melanoma
2
Endometrial Neoplasms
2
Solid Tumors
1
Sarcoma
1
Rectal Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Neoplasms
1
Nasopharangeal Cancer
1
Lymphoma, T-Cell, Peripheral
1
Lung Neoplasms
1
Kidney Neoplasms
1
Kidney Diseases
1
Hemangiosarcoma
1
Glioma
1
Glioblastoma
1
Fibrolamellar hepatocellular carcinoma
1
Esophageal Squamous Cell Carcinoma
1
Diffuse Intrinsic Pontine Glioma
1
CRC
1
Interventions
pembrolizumab
22
Nivolumab
14
enfortumab vedotin
12
Gemcitabine
11
Specimen Handling
10
Magnetic Resonance Spectroscopy
10
Cisplatin
8
Carboplatin
8
avelumab
7
sacituzumab govitecan
6
Docetaxel
6
atezolizumab
5
Ipilimumab
5
durvalumab
4
Paclitaxel
4
cabozantinib
3
Taxes
3
Mitomycin
3
Immunoglobulin G
3
CTLA-4 Antigen
3
tislelizumab
2
relatlimab
2
erdafitinib
2
disitamab vedotin
2
Radiosurgery
2
Platinum
2
Oxaliplatin
2
Fluorouracil
2
Disulfides
2
Cyclophosphamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Carcinoma, Transitional Cell
×
spartalizumab
×
90 days
×
Clear all
No trials found.